Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Arcadia Biosciences Q4 EPS $(2.10) Beats $(2.58) Estimate, Sales $1.17M Miss $1.75M Estimate

Author: Benzinga Newsdesk | March 28, 2024 05:27pm
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.10) per share which beat the analyst consensus estimate of $(2.58) by 18.6 percent. This is a 66.72 percent increase over losses of $(6.31) per share from the same period last year. The company reported quarterly sales of $1.17 million which missed the analyst consensus estimate of $1.75 million by 33.14 percent. This is a 17.00 percent increase over sales of $1.00 million the same period last year.

Posted In: RKDA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist